Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.53 |
| ▸ | CA1 | P00915 | 3/20 | 0.53 |
| ▸ | CA2 | P00918 | 3/20 | 0.53 |
| ▸ | CA7 | P43166 | 3/20 | 0.53 |
| ▸ | CA9 | Q16790 | 3/20 | 0.53 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.53 |
| ▸ | ESR1 | P03372 | 1/20 | 0.48 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | NPC1 | O15118 | 3/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4474538 | 0.84 | ESR1 (0.58) | ESR1CYP1A2LMNACYP3A4CYP2C9 | |
| SCHEMBL3016097 | 0.83 | CA12 (0.52) | CA12CA1CA2CA7CA9 | |
| SCHEMBL5737653 | 0.83 | CA12 (0.52) | CA12CA1CA2CA7CA9 | |
| SCHEMBL8627462 | 0.81 | CA12 (0.50) | CA12CA1CA2CA7CA9 | |
| SCHEMBL623423 | 0.81 | CA12 (0.50) | CA12CA1CA2CA7CA9 | |
| SCHEMBL8626938 | 0.81 | CA12 (0.50) | CA12CA1CA2CA7CA9 | |
| SCHEMBL6087188 | 0.81 | CYP1A2 (0.53) | CA12CA1CA2CA7CA9 | |
| SCHEMBL13141321 | 0.80 | MAPT (0.54) | CA12CA1CA2CA7CA9 | |
| SCHEMBL13268978 | 0.80 | CYP2C9 (0.50) | CA12CA1CA2CA7CA9 | |
| SCHEMBL9371320 | 0.80 | CA12 (0.49) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024129395-A1 | BTK INHIBITORS | GWYNANT THERAPEUTICS, INC. (US) | 2024-06-20 | — | — | WO | disclosed |
| WO-2024129395-A1 | BTK INHIBITORS | GWYNANT THERAPEUTICS, INC. (US) | 2024-06-20 | — | — | WO | disclosed |
| US-20160200639-A1 | INTERMOLECULAR C-H SILYLATION OF UNACTIVATED ARENES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2016-07-14 | — | — | US | disclosed |
| US-8461207-B2 | Phloroglucinol derivatives having selectin ligand activity | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2013-06-11 | — | — | US | disclosed |
| US-8278356-B2 | — | — | 2012-10-02 | — | — | US | disclosed |
| US-8198456-B2 | e.g. 1,4-dihydro-4-(1H-indazol-5-yl)-2,6-dimethyl-3,5-pyridinedicarbonitrile; c-Met tyrosine kinase inhibitor; antitumor agent; lung, liver, gastric and breast solid tumors; pancreatic cancer, glioma, and hepatocellular carcinoma | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-06-12 | — | — | US | disclosed |
| US-8198456-B2 | e.g. 1,4-dihydro-4-(1H-indazol-5-yl)-2,6-dimethyl-3,5-pyridinedicarbonitrile; c-Met tyrosine kinase inhibitor; antitumor agent; lung, liver, gastric and breast solid tumors; pancreatic cancer, glioma, and hepatocellular carcinoma | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-06-12 | — | — | US | disclosed |
| EP-2408743-A1 | CARBAMATE DERIVATIVES IN PARTICULAR FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. (IT) | 2012-01-25 | — | — | EP | disclosed |
| US-20110142765-A1 | NOVEL PHLOROGLUCINOL DERIVATIVES HAVING SELECTIN LIGAND ACTIVITY | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2011-06-16 | — | — | US | disclosed |
| US-20110053939-A1 | NOVEL AROMATIC NITRO COMPOUNDS | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2011-03-03 | — | — | US | disclosed |
| US-7622464-B2 | Morpholinyl-urea derivatives for use in the treatment of inflammatory diseases | GLAXO GROUP LIMITED (GB) | 2009-11-24 | — | — | US | disclosed |
| US-7622464-B2 | Morpholinyl-urea derivatives for use in the treatment of inflammatory diseases | GLAXO GROUP LIMITED (GB) | 2009-11-24 | — | — | US | disclosed |
| US-7608727-B2 | Process for the preparation of furan compounds | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2009-10-27 | — | — | US | disclosed |
| EP-1487828-B1 | MORPHOLINYL-UREA DERIVATIVES FOR USE OF THE TREATMENT OF INFLAMATORY DISEASES | GLAXO GROUP LTD (GB) | 2008-11-05 | — | — | EP | disclosed |
| US-20080176833-A1 | DIHYDROPYRIDINE DERIVATIVES AS USEFUL AS PROTEIN KINASE INHIBITORS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2008-07-24 | — | — | US | disclosed |
| US-20080176833-A1 | DIHYDROPYRIDINE DERIVATIVES AS USEFUL AS PROTEIN KINASE INHIBITORS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2008-07-24 | — | — | US | disclosed |
| EP-1826202-A1 | Process for the preparation of furan compounds | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2007-08-29 | — | — | EP | disclosed |
| US-20070197806-A1 | Process for the preparation of furan compounds | DAICEL CHEMICAL INDUSTRIES, LTD. | 2007-08-23 | — | — | US | disclosed |
| US-6114358-A | Thrombin inhibitors | BASF AKTIENGESELLSCHAFT (DE) | 2000-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160200639-A1 | INTERMOLECULAR C-H SILYLATION OF UNACTIVATED ARENES | CCNH, CTTN, CCRL2 | CA12 620/4885CA1 636/4885CA2 1245/4885 |
| US-20070197806-A1 | Process for the preparation of furan compounds | CBR1, CBR3, POR | CA12 3250/4885CA1 1850/4885CA2 2682/4885 |
| US-20080176833-A1 | DIHYDROPYRIDINE DERIVATIVES AS USEFUL AS PROTEIN KINASE INHIBITORS | MET, DMPK, RET | CA12 4405/4885CA1 3884/4885CA2 1821/4885 |
| US-20110053939-A1 | NOVEL AROMATIC NITRO COMPOUNDS | SELP, SELE, SELL | CA12 4570/4885CA1 4799/4885CA2 4231/4885 |
| US-20110142765-A1 | NOVEL PHLOROGLUCINOL DERIVATIVES HAVING SELECTIN LIGAND ACTIVITY | SELPLG, SELP, SELL | CA12 3936/4885CA1 4744/4885CA2 4489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.